Altor BioScience
Researches and develops immunotherapeutic agents for the treatment of cancer, viral infections and autoimmune diseases.
| Date | Investors | Amount | Round |
|---|---|---|---|
| - | investor investor | €0.0 | round |
| investor | €0.0 | round | |
| N/A | €0.0 | round | |
| investor investor | €0.0 | round | |
| N/A | €0.0 | round | |
| investor | €0.0 | round | |
| N/A | €0.0 | round | |
| N/A | €0.0 | round | |
| N/A | €0.0 | round | |
| N/A | €0.0 | round | |
| N/A | €0.0 | round | |
| N/A | €0.0 | round | |
| N/A | €0.0 | round | |
| investor investor investor | €0.0 | round | |
| N/A | €0.0 | round | |
| N/A | €0.0 | round | |
$290m | Acquisition | ||
| Total Funding | 000k | ||
Related Content
ImmunityBio, Inc. is a privately held immunotherapy company specializing in the development of advanced biological molecules to treat cancer and infectious diseases. The company operates in the biotechnology sector, focusing on creating therapies that harness the body's immune system to fight diseases. ImmunityBio serves a diverse range of clients, including healthcare providers, research institutions, and pharmaceutical companies. The company’s business model revolves around research and development, clinical trials, and partnerships with other biotech firms to bring innovative treatments to market. Revenue is generated through licensing agreements, product sales, and collaborative research funding. ImmunityBio's portfolio includes albumin-linked chemotherapeutics, peptides, fusion proteins, cytokines, monoclonal antibodies, and both adenovirus and yeast vaccine therapies. The company is also actively involved in the development of a novel adenovirus COVID-19 vaccine, showcasing its commitment to addressing urgent global health challenges.
Keywords: immunotherapy, biological molecules, cancer treatment, infectious diseases, biotechnology, clinical trials, partnerships, COVID-19 vaccine, monoclonal antibodies, cytokines.